Oncotarget

Clinical Research Papers:

Development and validation of a pretreatment prognostic index to predict death and lung metastases in extremity osteosarcoma

Bo Wang, Jian Tu, Junqiang Yin, Changye Zou, Jin Wang, Gang Huang, Xianbiao Xie _ and Jingnan Shen

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:38348-38359. https://doi.org/10.18632/oncotarget.5276

Metrics: PDF 861 views  |   HTML 1017 views  |   ?  


Abstract

Bo Wang1,*, Jian Tu1,*, Junqiang Yin1, Changye Zou1, Jin Wang1, Gang Huang1, Xianbiao Xie1, Jingnan Shen1

1Musculoskeletal Oncology Center, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China

*These authors have contributed equally to this work

Correspondence to:

Xianbiao Xie, e-mail: xiexianbiao@hotmail.com

Jingnan Shen, e-mail: shenjn01@hotmail.com

Keywords: osteosarcoma, survival outcomes, lung metastases, pretreatment prognostic index

Received: May 16, 2015     Accepted: September 18, 2015     Published: October 01, 2015

ABSTRACT

Background: To develop a prognostic index to predict the 5-year overall survival (OS) and 5-year lung metastasis-free survival (LMFS) of patients with extremity osteosarcoma at the time of diagnosis.

Methods: We retrospectively evaluated 454 patients with extremity osteosarcoma at our center from 2005 to 2013. The cohort was randomly divided into training and validation sets. The association of potential risk factors with OS and LMFS was assessed by Cox proportional hazards analysis in the training set, and a prognostic index was created according to scores that were proportional to a regression coefficient for each factor. This prognostic index was assessed in the validation set.

Results: For the 5-year OS, 5 independent prognostic factors were identified: tumor size, Enneking stage, pretreatment platelet, alkaline phosphatase(ALP), and neutrophils. The multivariate Cox model identified tumor size, pretreatment platelets, ALP, and neutrophils as associated with the 5-year LMFS. A prognostic index for death and lung metastases was calculated. Three risk groups were defined for each survival point: low, intermediate, and high risk for the 5-year OS; low, intermediate, and high risk for the 5-year LMFS. The C statistic for the 5-year OS was 0.723 in the training set and 0.710 in the validation set. The C statistic for the 5-year LMFS was 0.661 and 0.693 respectively.

Conclusion: This prognostic index is based on routine tests and characteristics of extremity osteosarcoma patients and is a useful predictor of OS and lung metastases. This index could be applied to clinical practice and trials for individualized risk-adapted therapies.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 5276